In a patient with acute coronary syndrome, should I use ticagrelor or clopidogrel as the antiplatelet therapy?

Ticagrelor versus Clopidogrel in Acute Coronary Syndrome

For patients with acute coronary syndrome, ticagrelor (180 mg loading dose, 90 mg twice daily) should be used instead of clopidogrel as the P2Y12 inhibitor combined with low-dose aspirin (75-100 mg daily), unless contraindications exist. 1, 2

Guideline-Based Hierarchy of P2Y12 Inhibitor Selection

The 2025 ACC/AHA/SCAI guidelines establish a clear preference hierarchy for ACS patients:

First-Line Therapy

• Ticagrelor is the preferred P2Y12 inhibitor for all ACS presentations (STEMI, NSTEMI, unstable angina), regardless of whether patients undergo PCI, receive medical management alone, or proceed to CABG 1, 2
• The 2025 ACC/AHA guidelines give ticagrelor a Class 1 (strong) recommendation for NSTE-ACS patients undergoing PCI and for STEMI patients managed with primary PCI 1
• The European Society of Cardiology similarly recommends ticagrelor as first-line therapy for all ACS patients, including those previously treated with clopidogrel (which should be discontinued when ticagrelor is commenced) 2

When Clopidogrel Should Be Used Instead

• Clopidogrel is recommended only when ticagrelor or prasugrel are unavailable, cannot be tolerated, or are contraindicated 1, 2
• Specific scenarios favoring clopidogrel include:
  • Prior intracranial hemorrhage 2
  • Need for concurrent oral anticoagulation (triple therapy), where clopidogrel carries substantially lower bleeding risk than ticagrelor 2
  • Severe renal impairment (creatinine clearance <30 mL/min), as ticagrelor lacks robust safety data in this population 2
  • Excessive baseline bleeding risk (e.g., PRECISE-DAPT score ≥25) 2, 3

Evidence Supporting Ticagrelor Superiority

The landmark PLATO trial provides the foundation for ticagrelor's preferential recommendation:

Ischemic Benefit

• Ticagrelor reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke by 16% compared to clopidogrel (9.8% vs 11.7%, HR 0.84,95% CI 0.77-0.92, P<0.001) 4
• Cardiovascular mortality was reduced by 21% (4.0% vs 5.1%, P=0.001) 4
• All-cause mortality was reduced by 24% (4.5% vs 5.9%, P<0.001) 4
• Myocardial infarction was reduced (5.8% vs 6.9%, P=0.005) 4

Bleeding Risk Trade-Off

• Major bleeding rates were similar overall (11.6% for ticagrelor vs 11.2% for clopidogrel, P=0.43) 4
• Non-CABG-related major bleeding was higher with ticagrelor (4.5% vs 3.8%, P=0.03), including more fatal intracranial bleeds (0.1% vs 0.01%, P=0.02) 4
• However, a 2022 meta-analysis found clopidogrel resulted in reduced risk of clinically significant bleeding (-1.9%, 95% CI -3.7% to -0.2%) and major bleeding (-0.9%, 95% CI -1.6% to -0.1%) 5

Real-World Evidence Shows Nuance

• A 2020 large-scale propensity-matched study (31,290 pairs) found no significant difference in net adverse clinical events between ticagrelor and clopidogrel at 12 months (15.1% vs 14.6%, HR 1.05,95% CI 1.00-1.10, P=0.06) 6
• Ticagrelor was associated with significantly higher hemorrhagic events (2.1% vs 1.6%, HR 1.35,95% CI 1.13-1.61, P=0.001) and dyspnea (27.3% vs 22.6%, HR 1.21,95% CI 1.17-1.26, P<0.001) 6
• A 2023 Canadian real-world study found ticagrelor reduced MACE (HR 0.79,95% CI 0.67-0.93, P<0.01) and hospitalization (HR 0.85,95% CI 0.77-0.95, P<0.01) without increased major bleeding 7

Despite mixed real-world data, the 2025 guidelines prioritize the PLATO trial's mortality benefit, maintaining ticagrelor's preferential recommendation. 1

Practical Dosing Algorithm

Ticagrelor Regimen (Preferred)

• Loading dose: 180 mg orally at presentation 1, 2
• Maintenance: 90 mg orally twice daily 1, 2
• Aspirin dose: Must be 75-100 mg daily (≤100 mg specifically recommended with ticagrelor to minimize bleeding) 1, 2
• Duration: 12 months for all ACS patients 1, 2

Clopidogrel Regimen (When Ticagrelor Contraindicated)

• Loading dose: 300-600 mg orally (600 mg preferred for faster onset) 1, 2, 8
• Maintenance: 75 mg orally daily 1, 8
• Aspirin dose: 75-100 mg daily 2
• Duration: 12 months for all ACS patients 1, 2

Special Dosing Considerations

• For STEMI patients >75 years receiving fibrinolytic therapy, clopidogrel loading dose should be 300 mg (or 75 mg initial dose if >75 years) 1
• Clopidogrel requires hepatic conversion to active metabolite via CYP2C19; poor metabolizers (homozygous for nonfunctional CYP2C19 alleles) have reduced antiplatelet effect 8
• Consider alternative P2Y12 inhibitor in identified CYP2C19 poor metabolizers 8

Critical Bleeding Risk Mitigation Strategies

Every ACS patient on dual antiplatelet therapy requires these measures:

• Proton pump inhibitor (PPI) co-prescription is mandatory to reduce gastrointestinal bleeding (Class I recommendation) 2
• Maintain low-dose aspirin at 75-100 mg daily; higher doses increase bleeding without added benefit 1, 2
• Use radial over femoral access for coronary angiography/PCI when performed by an expert radial operator 2
• Avoid premature discontinuation within the first month after stent placement, as this dramatically increases stent thrombosis risk 2

Risk-Stratified Approach

High Bleeding Risk Patients

• Clopidogrel is preferred over ticagrelor when excessive bleeding risk exists (PRECISE-DAPT score ≥25 or prolonged prothrombin time) 2, 3
• Consider shortened DAPT duration of 6 months instead of 12 months 2, 3
• Maintain all bleeding mitigation strategies (PPI, low-dose aspirin, radial access) 3

Patients Requiring Oral Anticoagulation

• Discontinue aspirin 1-4 weeks after PCI and continue P2Y12 inhibitor plus anticoagulant 2
• Clopidogrel is strongly preferred over ticagrelor in this setting due to substantially lower bleeding risk 2
• Triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) should be limited to maximum 6 months or omitted after discharge 2

Intermediate-to-High Ischemic Risk Patients

• A 2023 Chinese study using GRACE risk score stratification found ticagrelor reduced ischemic events in intermediate-to-high-risk patients (HR 0.60,95% CI 0.41-0.89, P=0.01) without increased BARC 3-5 bleeding 9
• Low-risk patients (GRACE score <109) showed no ischemic benefit from ticagrelor but had excess BARC 3-5 bleeding (HR 1.59,95% CI 1.16-2.17, P=0.004) 9

Common Pitfalls to Avoid

• Do not use clopidogrel as first-line therapy when ticagrelor is available and not contraindicated; this represents suboptimal guideline-directed care 1, 2
• Do not use aspirin doses >100 mg daily with ticagrelor, as this increases bleeding without improving efficacy 1, 2
• Do not omit PPI co-prescription, as this simple intervention significantly reduces gastrointestinal bleeding 2
• Do not discontinue DAPT within the first month after stent placement for elective surgery; delay surgery if possible or maintain aspirin at minimum 2
• Do not use ticagrelor in patients requiring oral anticoagulation without careful consideration; clopidogrel is safer in this setting 2
• Do not ignore CYP2C19 poor metabolizer status when using clopidogrel; these patients have reduced antiplatelet effect and should receive ticagrelor instead 8
• Do not switch from ticagrelor to clopidogrel during the 12-month DAPT period without a compelling contraindication (e.g., intolerable dyspnea, major bleeding) 2

When to Switch from Clopidogrel to Ticagrelor

• Patients presenting on chronic clopidogrel therapy should be switched to ticagrelor immediately upon ACS diagnosis 2
• Give ticagrelor 180 mg loading dose without waiting for clopidogrel washout 2
• This recommendation applies regardless of timing and loading dose of prior clopidogrel 2